ClinicalTrials.gg
Status unknownNCT01494779Updated Sep 25, 2012

Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.

A Phase 1 interventional study of Somatropin and Somatropin in GH Deficiency (GHD) and Growth Retardation, sponsored by Azidus Brasil. Status unknown at 1 site in Brazil. Open to male participants aged 18 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-09-25.

Sponsored by Azidus Brasil · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2012), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 32 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
39th of 60
32 · median 66
Started
2013
with 1 other
Phase 1
6 of 60
none open now
Registered
40th of 60
by date

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 39th largest by planned enrollment, is one of 2 that started in 2013, is one of 6 in phase 1, and was the 40th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 32 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the pharmacokinetic and pharmacodynamic effect between two preparations of somatropin (T and C) after a single administration of 5 mg in healthy subjects by altering serum somatropin pharmacokinetic parameters (AUC0-24h, AUC0-inf, Cmax, Tmax and T1 / 2) and pharmacodynamic (measurement of serum levels of IGF-1 presented by the concentration-time profile, AUC 0-24h and AUC0-inf.).

Read the detailed description

Secondly, the investigators will observe the clinical safety and tolerability after single dose administration in subjects, by comparing clinical parameters and the incidence of adverse events between groups.

03

Conditions studied

  • GH Deficiency (GHD)
  • Growth Retardation

Browse trials for

Keywords

  • children
04

Who can participate

Ages eligible
18 Years to 32 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Research subjects who agree with all study procedures, sign and date, of their own free will, the IC;
  2. Research subjects were male, aged between 18 and 32 years;
  3. Research subjects with greater than or equal to 20 and less than or equal to 25;
  4. Considered healthy subjects, both clinical and laboratory.

Exclusion criteria

Exclusion Criteria:

  1. Have donated or lost 450 mL or more blood in the 6 months preceding the study;
  2. Having participated in any experimental study or have taken any experimental drug in the 12 months preceding the start of the study;
  3. Having made use of regular medication less than two weeks to interfere with the pharmacokinetics / pharmacodynamics of the drug under study, such as , anabolic steroids, androgens, estrogens and thyroid hormones;
  4. Present history of alcohol abuse, drug or drugs;
  5. Have a history of liver disease, renal, pulmonary, gastrointestinal, hematologic, or psychiatric;
  6. Have made previous use of somatropin;
  7. Make use of energy supplements and / or be frequent consumers of soy products (eg replacement of animal milk for soy milk).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Somatropin Test

    Somatropin of Blausiegel Indústria e Comércio Ltda.

    Drug: Somatropin

  • Active comparator
    Saizen

    Somatropin of Merck Serono

    Drug: Somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint will be based in the investigation of pharmacokinetics and pharmacodynamics of somatropin in research subjects after administration of single dose, sc, of the drug.

    Pharmacokinetic evaluation will be based on data obtained from the average dosage of somatropin plasma. Thus, the time of collection facilities provide the pharmacokinetic parameters AUC0-24h, AUC0-inf, Cmax, Tmax and T1 / 2, which will be compared between the two formulations. The quantification of serum somatropin kit will be performed by ELISA validated using human serum as a biological matrix. The evaluation of the pharmacodynamics will be performed by quantifying serum levels of IGF-1 presented by the concentration-time profile, AUC 0-24h and AUC0-inf.

    Time frame: PK: 0, 1, 2, 3, 3:30, 4, 4:30, 5, 6, 9, 12, 15, 18, 24 hours. PD: 0, 6, 12, 24 hours.

Secondary outcomes

  1. After administration of the drug will be evaluated for safety and tolerability of the drug through the presence of hematoma, pain, itching and local redness, as well as the incidence of adverse events directly related to somatropin.

    Time frame: 15 weeks

07

Study locations

1 site
  • LAL Clínica Pesquisa e Desenvolvimento Ltda
    Valinhos, São Paulo, Brazil
    • Alexandre Frederico, phsycian · Contactalexandre@lalclinica.com.br · 55 19 3871-6399
    • Alexandre Frederico, phsycian · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jun 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2011
First posted
Dec 19, 2011
Start
Mar 2013
Primary completionEst.
Jun 2013
CompletionEst.
Aug 2013
Last update
Sep 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01494779
Lead sponsor
Azidus Brasil
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Mar 2013
Primary completion
Jun 2013 (estimated)
Completion
Aug 2013 (estimated)
Last update
Sep 25, 2012

Study contacts

Alexandre Frederico, physian
Contact
alexandre@lalclinica.com.br
55 19 3871-6399
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion